ReviewBlood reviews2014
The pathogenesis and treatment of large granular lymphocyte leukemia.
Review in Blood reviews, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 79 citations in OpenAlex.
- Stat3 mutations impact on overall survival in large granular lymphocyte leukemia: a single-center experience of 205 patients.Leukemia · 2020Trial
- TCR γδ cell-specific STAT5 gain of function induces a druggable chronic human immune dysregulation.Journal of human immunity · 2026Article
- Alemtuzumab for haematological malignancies.Annals of hematology · 2025Review
- T Cell Repertoire Analysis as a Molecular Signature of the Spectrum of T-LGL Lymphoproliferative Disorders: Tracing the Literature.Current issues in molecular biology · 2025Review
- Clinical features and influencing factors analysis of T-cell large granular lymphocytic leukemia complicated with pure red cell aplasia.Frontiers in immunology · 2025Article
- Large Granular Lymphocytic Leukemia: Clinical Features, Molecular Pathogenesis, Diagnosis and Treatment.Cancers · 2024Review
- A Comparison of the Fifth World Health Organization and the International Consensus Classifications of Mature T-Cell Lymphomas.International journal of molecular sciences · 2023Review
- Context-dependent T-cell Receptor Gene Repertoire Profiles in Proliferations of T Large Granular Lymphocytes.HemaSphere · 2023Article
- A case report of T-LGL leukemia-associated pure red cell aplasia harboring STAT3, TNFAIP3, and KMT2D mutation.Translational cancer research · 2023Article
- [T-large granular lymphocytic leukemia presenting as aplastic anemia: a report of five cases and literature review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Review
- Article
- Article
- Single-cell RNA sequencing coupled to TCR profiling of large granular lymphocyte leukemia T cells.Nature communications · 2022Article
- Large granular lymphocytic leukemia: a brief review.American journal of blood research · 2022Review
- Large Granular Lymphocytic Leukemia: From Immunopathogenesis to Treatment of Refractory Disease.Cancers · 2021Review
- Case Report: Endocapillary Glomerulopathy Associated With Large Granular T Lymphocyte Leukemia.Frontiers in immunology · 2021Article
- Sphingosine kinase-2 is overexpressed in large granular lymphocyte leukaemia and promotes survival through Mcl-1.British journal of haematology · 2020Article
- [Clinical and laboratory characteristics in patients with myeloid neoplasms complicated with clonal T large granular lymphocyte proliferation].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020Article
- [Clinical and laboratory analysis of 17 patients with γδT-cell large granular lymphocyte leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Large granular lymphocyte (LGL) leukemia is a spectrum of rare lymphoproliferative diseases of T lymphocytes and natural killer cells. These diseases frequently present with splenomegaly, neutropenia, and autoimmune diseases like rheumatoid arthritis. LGL leukemia is more commonly of a chronic, indolent nature; however, rarely, they have an aggressive course. LGL leukemia is thought to arise from chronic antigen stimulation, which drives long-term cell survival through the activation of survival signaling pathways and suppression of pro-apoptotic signals. These include Jak-Stat, Mapk, Pi3k-Akt, sphingolipid, and IL-15/Pdgf signaling. Treatment traditionally includes immunosuppression with low dose methotrexate, cyclophosphamide, and other immunosuppressive agents; however, prospective and retrospective studies reveal very limited success. New studies surrounding Jak-Stat signaling suggest this may reveal new avenues for LGL leukemia therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.